21 research outputs found
array CGH screening of 134 unrelated families
Background A growing number of non-coding regulatory mutations are being
identified in congenital disease. Very recently also some exons of protein
coding genes have been identified to act as tissue specific enhancer elements
and were therefore termed exonic enhancers or âeExonsâ. Methods We screened a
cohort of 134 unrelated families with split-hand/split-foot malformation
(SHFM) with high resolution array CGH for CNVs with regulatory potential.
Results In three families with an autosomal dominant non-syndromic SHFM
phenotype we detected microdeletions encompassing the exonic enhancer (eExons)
15 and 17 of DYNC1I1. In a fourth family, who had hearing loss in addition to
SHFM, we found a larger deletion of 510 kb including the eExons of DYNC1I1
and, in addition, the human brain enhancer hs1642. Exons 15 and 17 of DYNC1I1
are known to act as tissue specific limb enhancers of DLX5/6, two genes that
have been shown to be associated with SHFM in mice. In our cohort of 134
unrelated families with SHFM, deletions of the eExons of DYNC1I1 account for
approximately 3% of the cases, while 17p13.3 duplications were identified in
13% of the families, 10q24 duplications in 12%, and TP63 mutations were
detected in 4%. Conclusions We reduce the minimal critical region for SHFM1 to
78 kb. Hearing loss, however, appears to be associated with deletions of a
more telomeric region encompassing the brain enhancer element hs1642. Thus,
SHFM1 as well as hearing loss at the same locus are caused by deletion of
regulatory elements. Deletions of the exons with regulatory potential of
DYNC1I1 are an example of the emerging role of exonic enhancer elements and
their implications in congenital malformation syndromes
Construction and accessibility of a cross-species phenotype ontology along with gene annotations for biomedical research
Construction and accessibility of a cross-species phenotype ontology along with gene annotations for biomedical research
Phenotype analyses, e.g. investigating metabolic processes, tissue formation, or organism behavior, are an important element of most biological and medical research activities. Biomedical researchers are making increased use of ontological standards and methods to capture the results of such analyses, with one focus being the comparison and analysis of phenotype information between species. We have generated a cross-species phenotype ontology for human, mouse and zebrafish that contains classes from the Human Phenotype Ontology, Mammalian Phenotype Ontology, and generated classes for zebrafish phenotypes. We also provide up-to-date annotation data connecting human genes to phenotype classes from the generated ontology. We have included the data generation pipeline into our continuous integration system ensuring stable and up-to-date releases. This article describes the data generation process and is intended to help interested researchers access both the phenotype annotation data and the associated cross-species phenotype ontology. The resource described here can be used in sophisticated semantic similarity and gene set enrichment analyses for phenotype data across species. The stable releases of this resource can be obtained from http://purl.obolibrary.org/obo/hp/uberpheno/
Phenotypic overlap in the contribution of individual genes to CNV pathogenicity revealed by cross-species computational analysis of single-gene mutations in humans, mice and zebrafish
SUMMARY
Numerous disease syndromes are associated with regions of copy number variation (CNV) in the human genome and, in most cases, the pathogenicity of the CNV is thought to be related to altered dosage of the genes contained within the affected segment. However, establishing the contribution of individual genes to the overall pathogenicity of CNV syndromes is difficult and often relies on the identification of potential candidates through manual searches of the literature and online resources. We describe here the development of a computational framework to comprehensively search phenotypic information from model organisms and single-gene human hereditary disorders, and thus speed the interpretation of the complex phenotypes of CNV disorders. There are currently more than 5000 human genes about which nothing is known phenotypically but for which detailed phenotypic information for the mouse and/or zebrafish orthologs is available. Here, we present an ontology-based approach to identify similarities between human disease manifestations and the mutational phenotypes in characterized model organism genes; this approach can therefore be used even in cases where there is little or no information about the function of the human genes. We applied this algorithm to detect candidate genes for 27 recurrent CNV disorders and identified 802 gene-phenotype associations, approximately half of which involved genes that were previously reported to be associated with individual phenotypic features and half of which were novel candidates. A total of 431 associations were made solely on the basis of model organism phenotype data. Additionally, we observed a striking, statistically significant tendency for individual disease phenotypes to be associated with multiple genes located within a single CNV region, a phenomenon that we denote as pheno-clustering. Many of the clusters also display statistically significant similarities in protein function or vicinity within the protein-protein interaction network. Our results provide a basis for understanding previously un-interpretable genotype-phenotype correlations in pathogenic CNVs and for mobilizing the large amount of model organism phenotype data to provide insights into human genetic disorders
Functional Analysis of Alleged NOGGIN Mutation G92E Disproves Its Pathogenic Relevance
We identified an amino acid change (p.G92E) in the Bone Morphogenetic Protein antagonist NOGGIN in a 22-month-old boy who presented with a unilateral brachydactyly type B phenotype. Brachydactyly type B is a skeletal malformation that has been associated with increased Bone Morphogenetic Protein pathway activation in other patients. Previously, the amino acid change p.G92E in NOGGIN was described as causing fibrodysplasia ossificans progressiva, a rare genetic disorder characterized by limb malformations and progressive heterotopic bone formation in soft tissues that, like Brachydactyly type B, is caused by increased activation of Bone Morphogenetic Protein signaling. To determine whether G92E-NOGGIN shows impaired antagonism that could lead to increased Bone Morphogenetic Protein signaling, we performed functional assays to evaluate inhibition of BMP signaling. Interestingly, wt-NOGGIN shows different inhibition efficacies towards various Bone Morphogenetic Proteins that are known to be essential in limb development. However, comparing the biological activity of G92E-NOGGIN with wt-NOGGIN, we observed that G92E-NOGGIN inhibits activation of bone morphogenetic protein signaling with equal efficiency as wt-NOGGIN, supporting that G92E-NOGGIN does not cause pathological effects. Genetic testing of the child's parents revealed the same amino acid change in the healthy father, further supporting that p.G92E is a neutral amino acid substitution in NOGGIN. We conclude that p.G92E represents a rare polymorphism of the NOGGIN gene - causing neither brachydactyly nor fibrodysplasia ossificans progressiva. This study highlights that a given genetic variation should not be considered pathogenic unless supported by functional analyses
The Human Phenotype Ontology project:linking molecular biology and disease through phenotype data
The Human Phenotype Ontology (HPO) project, available at http://www.human-phenotype-ontology.org, provides a structured, comprehensive and well-defined set of 10,088 classes (terms) describing human phenotypic abnormalities and 13,326 subclass relations between the HPO classes. In addition we have developed logical definitions for 46% of all HPO classes using terms from ontologies for anatomy, cell types, function, embryology, pathology and other domains. This allows interoperability with several resources, especially those containing phenotype information on model organisms such as mouse and zebrafish. Here we describe the updated HPO database, which provides annotations of 7,278 human hereditary syndromes listed in OMIM, Orphanet and DECIPHER to classes of the HPO. Various meta-attributes such as frequency, references and negations are associated with each annotation. Several large-scale projects worldwide utilize the HPO for describing phenotype information in their datasets. We have therefore generated equivalence mappings to other phenotype vocabularies such as LDDB, Orphanet, MedDRA, UMLS and phenoDB, allowing integration of existing datasets and interoperability with multiple biomedical resources. We have created various ways to access the HPO database content using flat files, a MySQL database, and Web-based tools. All data and documentation on the HPO project can be found online
Deletions of exons with regulatory activity at the DYNC1I1 locus are associated with split-hand/split-foot malformation: array CGH screening of 134 unrelated families
Background: A growing number of non-coding regulatory mutations are being identified in congenital disease. Very recently also some exons of protein coding genes have been identified to act as tissue specific enhancer elements and were therefore termed exonic enhancers or "eExons".
Methods: We screened a cohort of 134 unrelated families with split-hand/split-foot malformation (SHFM) with high resolution array CGH for CNVs with regulatory potential.
Results: In three families with an autosomal dominant non-syndromic SHFM phenotype we detected microdeletions encompassing the exonic enhancer (eExons) 15 and 17 of DYNC1I1. In a fourth family, who had hearing loss in addition to SHFM, we found a larger deletion of 510 kb including the eExons of DYNC1I1 and, in addition, the human brain enhancer hs1642. Exons 15 and 17 of DYNC1I1 are known to act as tissue specific limb enhancers of DLX5/6, two genes that have been shown to be associated with SHFM in mice. In our cohort of 134 unrelated families with SHFM, deletions of the eExons of DYNC1I1 account for approximately 3% of the cases, while 17p13.3 duplications were identified in 13% of the families, 10q24 duplications in 12%, and TP63 mutations were detected in 4%.
Conclusions: We reduce the minimal critical region for SHFM1 to 78 kb. Hearing loss, however, appears to be associated with deletions of a more telomeric region encompassing the brain enhancer element hs1642. Thus, SHFM1 as well as hearing loss at the same locus are caused by deletion of regulatory elements. Deletions of the exons with regulatory potential of DYNC1I1 are an example of the emerging role of exonic enhancer elements and their implications in congenital malformation syndromes
wt-NOG and G92E-NOG show comparable ability to block BMP targets in the chicken Micromass system.
<p>Chicken micromass cells were infected with 1*10e07 viral particles/ml containing the gene for BMP2 (A), Bmp4 (B), Bmp7 (C) or GDF5 (D). Co-infection was performed with increasing virus titers of either wt-NOG or G92E-NOG as indicated. At day 5, cells were stained with Alcian blue, and dye concentration quantified spectrophotometrically at 595 nm. Controls infected exclusively with BMPs were normalized as 100% activity. Data shown are taken from a representative experiment performed with 3 replicates each. Error bars indicate standard deviation.</p
Three-dimensional model of the NOG-BMP7 complex highlighting the unstructured polyglycine loop that harbors the substitution in p.G92E.
<p>NOG-BMP7 complex (PDB: 1M4U) is depicted as a cartoon structure, with monomers of the NOG homodimer in dark in light green and monomers of the BMP7 homodimer in red and orange with surfaces depicted (A). Labeled residues flank the polyglycine loop, which is unresolved due to an apparent high flexibility associated with the largely unrestricted chain of residues. The NOG monomers on the left are tilted slightly into, and the BMP monomers slightly out of, the image plane. The complex in the zoomed view (B) is tilted further in the same direction, as well as slightly counter-clockwise about the perpendicular axis.</p
Biological activity of wt-NOG and G92E-NOG and protein production in chicken micromass cells are comparable.
<p>Chicken micromass cells were infected with either wt-NOG or G92E-NOG from 1*10e07 viral particles/ml and decreasing to 0.05*10e07 viral particles/ml (A). At day 5, cells were stained with Alcian blue, and dye concentration quantified spectrophotometrically at 595 nm. Non-infected controls were normalized as 100% activity. Data shown are taken from a representative experiment performed with 3 replicates each. Error bars indicate standard deviation. Pellets from cells infected with 1*10e07 viral particles/ml were collected at day 3 from the same chicken micromass experiment to perform Western Blot analysis (B). Uninfected cells were used as a control. After SDS-PAGE under non-reducing conditions and subsequent Western Blot, NOG and β-Actin were detected with specific antibodies. For quantification, NOG was normalized to β-Actin. Wt-NOG and G92E-NOG are expressed in equal amounts in the micromass cultures.</p